AB0263 Predictive value of a single measurement of the multi-biomarker disease activity (MBDA) score for disease flares within 6 and 12 months in rheumatoid arthritis patients using tumor necrosis factor inhibitors and conventional synthetic dmards

Abstract

BackgroundRheumatoid Arthritis (RA) patients in the maintenance phase should be treated by escalating antirheumatics up to stable low disease activity and then often are treated with tumor necrosis factor inhibitors...